The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase 3 study, we assigned 834 patients with advanced melanoma in a 1:1:1 ratio to receive pembrolizumab (at a dose of 10 mg per kilogram of body weight) every 2 weeks or every 3 weeks or four doses of ipilimumab (at 3 mg per kilogram) every 3 weeks. Primary end points were progression-free and overall survival. RESULTS: The estimated 6-month progression-free-survival rates were 47.3% for pembrolizumab every 2 weeks, 46.4% for pembrolizumab every 3 weeks, and 26.5% for ipilimumab (hazard ratio for disease progression, 0.58; P<0.001 for both pembrolizumab regimens versus ipilimumab; 95% confidence intervals [CIs], 0.46 to 0.72 and 0.47 to 0.72, respectively). Estimated 12-month survival rates were 74.1%, 68.4%, and 58.2%, respectively (hazard ratio for death for pembrolizumab every 2 weeks, 0.63; 95% CI, 0.47 to 0.83; P=0.0005; hazard ratio for pembrolizumab every 3 weeks, 0.69; 95% CI, 0.52 to 0.90; P=0.0036). The response rate was improved with pembrolizumab administered every 2 weeks (33.7%) and every 3 weeks (32.9%), as compared with ipilimumab (11.9%) (P<0.001 for both comparisons). Responses were ongoing in 89.4%, 96.7%, and 87.9% of patients, respectively, after a median follow-up of 7.9 months. Efficacy was similar in the two pembrolizumab groups. Rates of treatment-related adverse events of grade 3 to 5 severity were lower in the pembrolizumab groups (13.3% and 10.1%) than in the ipilimumab group (19.9%). CONCLUSIONS: The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp & Dohme; KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“however responses to these therapies are often heterogeneous and not durable (1–3).”
From Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients (2018) · cites this paper as [2]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of ICPis excluded patients with pre-existing active autoimmune diseases because of concerns of a high susceptibility to severe irAEs [49,50].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [50]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with anti-PD-1 and anti-PD-1/CTLA-4 combination therapy emerging as most effective [3, 4].”
From Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients (2019) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There were 16 responders (from here on, referred to as R) and 26 nonresponders (NR), yielding a response rate of 38%, which is in line with published clinical data of anti–PD-1 therapy in metastatic melanoma patients (5, 6).”
From The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients (2018) · cites this paper as [6]
In the citing paper
“Immune checkpoint blockade with monoclonal antibodies (mAbs) targeting programmed cell death protein 1 (PD-1) provides long-term clinical benefits to nearly 40% of patients with advanced melanoma (1–5).”
From Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients (2021) · cites this paper as [5]
In the citing paper
“Severe adverse reactions include severe diarrhea, colitis, increased alanine aminotransferase levels, inflammation pneumonitis, and interstitial nephritis (67, 73, 99).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [73]
In the citing paper
“In the subsequent phase III clinical trial, more than 30% of patients with advanced melanoma achieved an objective response following pembrolizumab monotherapy compared with 12% of patients treated with ipilimumab alone (58).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [58]
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [2]
In the citing paper
“In order to limit the risk of severe immune-related adverse events (irAEs) or exacerbation of underlying autoimmune or inflammatory disease, patients with preexisting autoimmune disorders (ADs) or those receiving systemic immunosuppression for organ transplantation have been universally excluded from clinical trials.3,4”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [4]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Self-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Research works printed but not linked: 2
- Ribas A, 2014, Pigment Cell Melanoma Res, 27, 1223
- Robert C, 2014, Ann Oncol, 25, LBA34
Cited by
Sorted by citations
Items 401–500 of 1,039
The landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 240
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 237
Trial Watch: Toll-like receptor agonists in cancer immunotherapy
Smith, M. M., García-Martínez, E., Pitter, M. R., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1526250 · Cited by 237
Girotti, M. R., Gremel, G., Lee, R. J., Galvani, E., Rothwell, D. G., Virós, A., Mandal, A. K., Lim, K. H. J., Saturno, G., Furney, S. J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1336 · Cited by 235
Self-citationMutational Landscape and Sensitivity to Immune Checkpoint Blockers
Chabanon, R. M., Pedrero, M., Lefèbvre, C., Marabelle, A., Soria, J., & Postel-Vinay, S. C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0903 · Cited by 236
Diverse types of dermatologic toxicities from immune checkpoint blockade therapy
Curry, J. L., Tetzlaff, M. T., Nagarajan, P., Drucker, C. R., Diab, A. K., Hymes, S. R., Duvic, M. A., Hwu, W., Wargo, J. A., Torres-Cabala, C. A., et al. (2016) · Journal of Cutaneous Pathology · doi:10.1111/cup.12858 · Cited by 235
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 237
Khoja, L., Butler, M. O., Kang, S. P., Ebbinghaus, S., & Joshua, A. M. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0078-9 · Cited by 235
Self-citationVedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Burugu, S., Asleh, K., & Nielsen, T. O. (2016) · Breast Cancer · doi:10.1007/s12282-016-0698-z · Cited by 234
Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233
“Introduction Cancer immunotherapy has succeeded in providing unprecedented clinical benefit to a subset of patients with many cancer types, including melanoma (1) and non–small cell lung cancer (2), while failing in others.”
BackgroundYi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Age-Specific Incidence of Melanoma in the United States
Paulson, K. G., Gupta, D., Kim, T. S., Veatch, J. R., Byrd, D. R., Bhatia, S., Wojcik, K. Y., Chapuis, A. G., Thompson, J. A., Madeleine, M. M., et al. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3353 · Cited by 232
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
Yan, Y., Kumar, A. B., Finnes, H. D., Markovic, S. N., Park, S. S., Dronca, R. S., & Dong, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01739 · Cited by 231
Cardiovascular Toxicities of Immune Checkpoint Inhibitors
Ball, S., Ghosh, R. K., Wongsaengsak, S., Bandyopadhyay, D., Ghosh, G. C., Aronow, W. S., Fonarow, G. C., Lenihan, D. J., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.079 · Cited by 231
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Lv, H., Liu, X., Zeng, X., Liu, Y., Zhang, C.-J., Zhang, Q., & Xu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930041 · Cited by 233
Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives
Birzu, C., French, P. J., Caccese, M., Cerretti, G., Idbaïh, A., Zagonel, V., & Lombardi, G. (2020) · Cancers · doi:10.3390/cancers13010047 · Cited by 229
da Silva, I. P., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Warner, A. B., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00097-8 · Cited by 229
Self-citationStrosberg, J., Mizuno, N., Doi, T., Grande, E., Delord, J., Shapira‐Frommer, R., Bergsland, E. K., Shah, M. H., Fakih, M., Takahashi, S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3014 · Cited by 227
Self-citationSubudhi, S. K., Aparicio, A., Gao, J., Zurita, A. J., Araujo, J. C., Logothetis, C. J., Tahir, S. A., Korivi, B. R., Slack, R. S., Vence, L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611421113 · Cited by 226
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 224
Self-citationGorris, M. A. J., Halilović, A., Rabold, K., van Duffelen, A., Wickramasinghe, I. N. A., Verweij, D. I., Wortel, I. M. N., Textor, J. C., de Vries, I. J. M., & Figdor, C. G. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701262 · Cited by 225
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Self-citationSystemic therapy of brain metastases: non–small cell lung cancer, breast cancer, and melanoma
Chamberlain, M. C., Baik, C. S., Gadi, V. K., Bhatia, S., & Chow, L. Q. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now197 · Cited by 224
Immunogenic Cell Death Amplified by Co-localized Adjuvant Delivery for Cancer Immunotherapy
Fan, Y., Kuai, R., Xu, Y., Ochyl, L. J., Irvine, D. J., & Moon, J. J. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03218 · Cited by 222
Mechanisms of immune evasion in bladder cancer
Crispen, P. L., & Kusmartsev, S. A. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02443-4 · Cited by 221
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
La-Beck, N. M., Jean, G. W., Huynh, C., Alzghari, S. K., & Lowe, D. B. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1643 · Cited by 220
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Gulley, J. L., Madan, R. A., Pachynski, R. K., Mulders, P., Sheikh, N. A., Trager, J. B., & Drake, C. G. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw261 · Cited by 220
Wang, D. Y., Ye, F., Zhao, S., & Johnson, D. B. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1344805 · Cited by 220
Cancer Neoantigens and Applications for Immunotherapy
Desrichard, A., Snyder, A., & Chan, T. A.-T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3175 · Cited by 219
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Grigg, C. M., & Rizvi, N. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0153-x · Cited by 219
Buder‐Bakhaya, K., & Hassel, J. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01474 · Cited by 219
Immune Checkpoint Inhibitor Therapy in Oncology
Tan, S., Day, D., Nicholls, S. J., & Segelov, E. (2022) · JACC CardioOncology · doi:10.1016/j.jaccao.2022.09.004 · Cited by 219
Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0336-8 · Cited by 218
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019
Garbe, C., Amaral, T. M. S., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V. A., del Mármol, V., Dréno, B., Fargnoli, M. C., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.11.015 · Cited by 218
Self-citationAdaptive Mechanisms of Tumor Therapy Resistance Driven by Tumor Microenvironment
Wu, P., Gao, W. Q., Su, M., Nice, E. C., Zhang, W., Lin, J., & Xie, N. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.641469 · Cited by 218
Dizon, D. S., Krilov, L., Cohen, E. E. W., Gangadhar, T. C., Ganz, P. A., Hensing, T. A., Hunger, S. P., Krishnamurthi, S., Lassman, A. B., Markham, M. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.8427 · Cited by 218
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Kaunitz, G. J., Cottrell, T. R., Lilo, M. T., Muthappan, V., Esandrio, J., Berry, S., Xu, H., Ogurtsova, A., Anders, R. A., Fischer, A. H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.64 · Cited by 216
Larkin, J., Vecchio, M. D., Mandalà, M., Gogas, H. J., Arance, A. M., Dalle, S., Cowey, C. L., Schenker, M., Grob, J., Chiarion‐Sileni, V., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3145 · Cited by 213
Self-citationTreatment of Advanced Prostate Cancer—A Review of Current Therapies and Future PromisePreprint
Sumanasuriya, S., & Bono, J. S. D. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030635 · Cited by 213
Lee, J. W., Komar, C. A., Bengsch, F., Graham, K. L., & Beatty, G. L. (2016) · Current Protocols in Pharmacology · doi:10.1002/cpph.2 · Cited by 212
VISTA expressed in tumour cells regulates T cell function
Mulati, K., Hamanishi, J., Matsumura, N., Chamoto, K., Mise, N., Abiko, K., Baba, T., Yamaguchi, K. D., Horikawa, N., Murakami, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0313-5 · Cited by 211
Kim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J., Lee, S., Ahn, J. S., Cheon, J., Min, Y. J., Park, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 211
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Wilky, B. A. (2019) · Immunological Reviews · doi:10.1111/imr.12766 · Cited by 214
Grabovska, Y., Mackay, A. G., O’Hare, P., Crosier, S., Finetti, M. A., Schwalbe, E. C., Pickles, J. C., Fairchild, A. R., Avery, A., Cockle, J. V., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18070-y · Cited by 211
Tobin, R. P., Jordan, K. R., Robinson, W. A., Davis, D. M., Borges, V. F., Gonzalez, R. C., Lewis, K. D., & McCarter, M. D. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.08.007 · Cited by 210
Emerging strategies for combination checkpoint modulators in cancer immunotherapy
Popović, A., Jaffee, E. M., & Zaidi, N. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120775 · Cited by 209
Elkrief, A., El Raichani, L., Richard, C., Messaoudene, M., Belkaid, W., Malo, J., Belanger, K., Miller, W., Jamal, R., Letarte, N., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1568812 · Cited by 208
“(PFS) and lower immune-mediated toxicities in comparison to ipilimumab alone.(3,4) Combinations of ICIs provide deeper response rates; however, toxicities remain the principal hurdle.”
BackgroundEngineering patient-specific cancer immunotherapies
Scheetz, L., Park, K. S., Li, Q., Lowenstein, P. R., Castro, M. G., Schwendeman, A., & Moon, J. J. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0436-x · Cited by 208
Guo, X., Jiang, H., Shi, B., Zhou, M., Zhang, H., Shi, Z., Du, G., Luo, H., Wu, X., Wang, Y., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01118 · Cited by 208
T cell exhaustion: from pathophysiological basics to tumor immunotherapy
Catakovic, K., Klieser, E., Neureiter, D., & Geisberger, R. (2017) · Cell Communication and Signaling · doi:10.1186/s12964-016-0160-z · Cited by 207
Osta, B. E. E., Hu, F., Sadek, R. A., Chintalapally, R., & Tang, S. C. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.09.002 · Cited by 208
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 210
Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy
Goldinger, S. M., Stieger, P., Meier-Schiesser, B., Micaletto, S., Contassot, E., French, L. E., & Dummer, R. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2872 · Cited by 205
Gutzmer, R., Koop, A., Meier, F. E., Hassel, J. C., Terheyden, P. A. M., Zimmer, L., Heinzerling, L., Ugurel, S., Pföhler, C., Gesierich, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.038 · Cited by 205
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman, P. M., Heeke, S., Alix‐Panabières, C., & Pantel, K. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz196 · Cited by 205
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Hossain, M. A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113365 · Cited by 213
Current progress in immunotherapy for pancreatic cancer
Foley, K., Kim, V., Jaffee, E. M., & Zheng, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 204
Finkelmeier, F., Canli, Ö., Tal, A. O., Pleli, T., Trojan, J., Schmidt, M., Kronenberger, B., Zeuzem, S., Piiper, A., Greten, F. R., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.002 · Cited by 204
Kuk, D., Shoushtari, A. N., Barker, C. A., Panageas, K. S., Munhoz, R. R., Momtaz, P., Ariyan, C. E., Brady, M. S., Coit, D. G., Bogatch, K., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0522 · Cited by 204
Neurological toxicities associated with immune-checkpoint inhibitors
Touat, M., Talmasov, D., Ricard, D., & Psimaras, D. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000503 · Cited by 204
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 208
Burel, S. L., Champiat, S., Mateus, C., Marabelle, A., Michot, J., Robert, C., Belkhir, R., Soria, J., Laghouati, S., Voisin, A.-L., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.032 · Cited by 203
Self-citationIndini, A., Di Guardo, L., Cimminiello, C., Prisciandaro, M., Randon, G., De Braud, F., & Del Vecchio, M. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2819-x · Cited by 202
Heppt, M. V., Heinzerling, L., Kähler, K. C., Forschner, A., Kirchberger, M. C., Loquai, C., Meißner, M., Meier, F. E., Terheyden, P. A. M., Schell, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.038 · Cited by 202
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
Arora, S., Velichinskii, R. A., Lesh, R. W., Ali, U., Kubiak, M. J., Bansal, P., Borghaei, H., Edelman, M. J., & Boumber, Y. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01051-z · Cited by 202
Sex- and Gender-Based Pharmacological Response to Drugs
Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 203
Role of PD-1 in Immunity and Diseases
Chamoto, K., Al-Habsi, M., & Honjo, T. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_67 · Cited by 200
A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy
Mi, Y., Smith, C. C., Yang, F., Qi, Y., Roche, K. C., Serody, J. S., Vincent, B. G., & Wang, A. Z. (2018) · Advanced Materials · doi:10.1002/adma.201706098 · Cited by 200
Chen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 203
Murakami, N., Mulvaney, P. M., Danesh, M. J., Abudayyeh, A., Diab, A. K., Abdel‐Wahab, N., Abdelrahim, M., Khairallah, P., Shirazian, S., Kukla, A., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.12.015 · Cited by 200
Tregs: Where We Are and What Comes Next?
Hai, Z., Liao, X., & Kang, Y. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01578 · Cited by 200
Manohar, S., Kompotiatis, P., Thongprayoon, C., Cheungpasitporn, W., Herrmann, J., & Herrmann, S. M. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy105 · Cited by 198
Park, Y., Kuen, D., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 198
Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
Egen, J. G., Ouyang, W., & Wu, L. C. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.010 · Cited by 198
Donlon, N., Power, R. F., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 199
Molecular approaches for classifying endometrial carcinoma
Piulats, J. M., Guerra, E., Gil-Martín, M., Roman‐Canal, B., Gatius, S., Pamplona, R. S., Velasco, A., Vidal, A., & Matías‐Guiu, X. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.12.015 · Cited by 197
Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
Cabel, L., Proudhon, C., Romano, E., Girard, N., Lantz, O. J., Stern, M., Pierga, J., & Bidard, F. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0074-3 · Cited by 197
Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Tan, L., Sandhu, S. K., Lee, R. J., Li, J., Callahan, J., Ftouni, S., Dhomen, N. S., Middlehurst, P., Wallace, A. J., Raleigh, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz048 · Cited by 196
Self-citationKnudson, K. M., Hicks, K. C., Luo, X., Chen, J.-Q., Schlom, J., & Gameiro, S. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1426519 · Cited by 195
Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab
England, C. G., Ehlerding, E. B., Hernandez, R. T., Rekoske, B. T., Graves, S. A., Sun, H., Liu, G., McNeel, D. G., Barnhart, T. E., & Cai, W. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.177857 · Cited by 195
Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
Vigarios, É., Epstein, J. B., & Sibaud, V. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3629-4 · Cited by 195
Schreuer, M. S., Jansen, Y. J. L., Planken, S., Chevolet, I., Seremet, T., Krüse, V., & Neyns, B. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30171-7 · Cited by 195
Self-citationCutaneous Malignant Melanoma: A Review of Early Diagnosis and Management
Naik, P. P. (2021) · World Journal of Oncology · doi:10.14740/wjon1349 · Cited by 195
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma
Warner, A. B., Nipp, R. D., Giobbie‐Hurder, A., Johnpulle, R. A. N., Rubin, K. M., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., & Sullivan, R. J. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0450 · Cited by 194
Immune checkpoint inhibitors and elderly people: A review
Daste, A., Domblides, C., Gross‐Goupil, M., Chakiba, C., Quivy, A., Cochin, V., de Monès, E., Larmonier, N., Soubeyran, P., & Ravaud, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.044 · Cited by 194
Pike, L., Bang, A., Mahal, B. A. V., Taylor, A., Krishnan, M. S., Spektor, A., Cagney, D. N., Aizer, A. A., Alexander, B. M., Rahma, O. E., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.09.010 · Cited by 194
Sun, F. Z., Zhu, Q., Li, T., Saeed, M., Xu, Z., Zhong, F., Song, R., Huai, M., Zheng, M., Xie, C., et al. (2021) · Advanced Science · doi:10.1002/advs.202002746 · Cited by 194
Zimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M. S., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 193
Recent progress in Lynch syndrome and other familial colorectal cancer syndromes
Boland, P. M., Yurgelun, M. B. B., & Boland, C. R. (2018) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21448 · Cited by 191
Gong, J., Le, T. Q., Massarelli, E., Hendifar, A. E., & Tuli, R. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0361-7 · Cited by 191
Immunotherapy Resistance by Inflammation-Induced Dedifferentiation
Mehta, A., Kim, Y. J., Robert, L., Tsoi, J., Comı́n-Anduix, B., Berent-Maoz, B., Cochran, A. J., Economou, J. S., Tumeh, P. C., Puig-Saus, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1178 · Cited by 191
Self-citationBai, X. L., Hu, J., Warner, A. B., Quach, H. T., Cann, C., Zhang, M. Z., Si, L., Tang, B., Cui, C., Yang, X., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1283 · Cited by 191
Self-citationSubrahmanyam, P. B., Dong, Z., Gusenleitner, D., Giobbie-Hurder, A., Severgnini, M., Zhou, J., Manos, M., Eastman, L. M., Maecker, H. T., & Hodi, F. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0328-8 · Cited by 190
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Self-citationCallahan, M. K., Kluger, H. M., Postow, M. A., Segal, N. H., Lesokhin, A. M., Atkins, M. B., Kirkwood, J. M., Krishnan, S., Bhore, R., Horak, C. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.2850 · Cited by 190
Hamid, O., Puzanov, I. J., Dummer, R., Schachter, J., DAUD, A. I., Schadendorf, D., Blank, C. U., Cranmer, L. D., Robert, C., Pavlick, A. C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.022 · Cited by 190
Self-citationLong-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade
Warner, A. B., Palmer, J. S., Shoushtari, A. N., Goldman, D. A., Panageas, K. S., Hayes, S. A., Bajwa, R., Momtaz, P., Callahan, M. K., Wolchok, J. D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01464 · Cited by 190
Metadata
- Authors
- Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C. U., Hamid, O., Mateus, C., Shapira-Frommer, R., Kosh, M., Zhou, H., Ibrahim, N., Ebbinghaus, S., & Ribas, A.
- Affiliations
- Université Paris-Sud (FR)
- Sheba Medical Center (IL)
- Hospital Clínic de Barcelona (ES)
- Hôpital de la Timone (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- University of California, San Francisco (US)
- Royal Prince Alfred Hospital (AU)
- Hadassah Medical Center (IL)
- Royal Marsden Hospital (GB)
- University of Manchester (GB)
- Universitair Ziekenhuis Brussel (BE)
- The Netherlands Cancer Institute (NL)
- Angeles Clinic and Research Institute (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2521-2532
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152897456
- Semantic Scholar
- 0dac3ea80083f0a86598cb9af0a205554280551b
- Cited by
- 5,887
- References
- 26
- Citations by year
- 2026: 234 · 2025: 298 · 2024: 374 · 2023: 421 · 2022: 471 · 2021: 568 · 2020: 659 · 2019: 585 · 2018: 684 · 2017: 761 · 2016: 628 · 2015: 188
- FWCI
- 329.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Genentech
- Kite Pharma
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- ipilimumab, advanced melanoma, immune checkpoint inhibitors, anti-PD-1 therapy, CTLA-4 inhibition, progression-free survival, overall survival, dosing frequency, treatment-related adverse events, immune-related adverse events, response rate
- MeSH terms
- Ipilimumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Male, Melanoma, Middle Aged, Skin Neoplasms, Survival Analysis, Young Adult, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
